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Abstract 
AIM: Colorectal cancer is the fourth common tumour in Egypt after lymphoid, breast and urinary tumours. The 
study aims to assess the expression of Lgr5 and CD133 in pre-malignant (adenomatous polyps and IBD), 
malignant colorectal lesions and normal colonic mucosa by immunohistochemical staining. 
MATERIAL AND METHODS: This prospective study was done on 100 patients presenting with colonic 
symptoms, patients were divided into four groups; group I including 20 patients in the control group, group II 
including 20 ulcerative colitis (U.C) patients, group III including 20 patients with adenomatous polyps and group IV 
including 40 patients with colorectal cancer (CRC).  
RESULTS: Lgr5 and CD133 expression was significantly higher in carcinoma than in adenomas, IBD and normal 
mucosa (P < 0.001). Lrg5 and CD133 was positively correlated with histological grade (P = 0.001), depth of 
invasion (P = 0.001), lymph node metastasis (P < 0.001), distant metastasis (P < 0.004) and TNM stage (P < 
0.001).  
CONCLUSION: Role of Lgr5 and CD133 as stem cell marker was expressed and presented with different 
expression in the normal colonic mucosa, adenoma and CRC and showed increased expression in an advanced 
stage of CRC. This may suggest its possible involvement in colorectal tumorigenesis and invasion. 
 
 
 
 
 
 
 
 
Introduction 
 
Worldwide, colorectal cancer is the third most 
commonly diagnosed cancer in males and the second 
in females [1]. Traditional models of tumorigenesis 
suggest that every cell within the tumour population is 
capable of tumour initiation and propagation. The 
newly discussed cancer stem cell (CSC) model, 
however, proposes that only a small fraction of cells 
possess tumour propagation abilities. This hypothesis 
raises questions regarding the efficiency of current 
diagnostic and therapeutic measures, suggesting that 
CSCs are a rational target for the development of 
robust diagnostic, therapeutic, and follow‐up 
strategies [2]. Many pieces of evidence suggest that 
cancer is a disease of stem cells [3] [4]. The cancer 
stem cell model was described for hematologic 
malignancies in 1997, and since then evidence has 
emerged to support it for many solid tumours as well, 
including colon cancer, this model proposes that 
certain cells within the tumour mass are pluripotent 
and capable of self-renewal and have an enhanced 
ability to initiate distant metastasis. Becker et al., [5] in 
their study suggest that (1) Lgr5 is a potential marker 
of intestinal stem cells in humans and (2) loss of 
restriction to the stem cell niche is an early event in 
the premalignant transformation of stem cells and may 
play a role in carcinogenesis. Femia et al., [6] found 
overexpression of Lgr5 in precancerous lesions and 
tumours, they support Lgr5 as putative neoplastic 
stem cell marker, and they identified Lgr5-positive 
cells are co-expressing nuclear β-catenin (NBC) which 
could be a subpopulation with the highest stem cell 
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features. CD133 (Prominin-1), a transmembrane 
glycoprotein which was first identified as a potential 
cancer stem cell (CSC) marker for brain tumours [7]. 
Both O’Brien et al., [8] and Ricci-Vitiani et al., [9] 
found that the tumours formed from CD133 positive 
cells injected into severe combined 
immunodeficiency (SCID) mice resembled a tumour 
from which they were taken and formed tumours of 
differentiated cell types that were mostly CD133 
negative. The CD133 negative cells from these 
tumours did not form metastases in mice even when 
injected at much higher numbers than CD133 positive 
cells. 
This aim of the study is designed to 
investigate the distribution and expression of 
immunostaining of Lgr5 and CD 133 proteins in stem 
cells of human colon in malignant and premalignant 
colonic lesions in Egyptian patients. 
 
 
Patients and Methods  
 
This prospective case-control study was 
conducted on 100 subjects who attended the 
Gastrointestinal Endoscopy unit in Nasser Institute for 
research and treatment Hospital, and in collaboration 
with Theodor Bilharz Research Institute, during the 
period from March 2015 to March 2017. Patients were 
categorised into four groups: 
Group I: included 20 patients had a normal 
colonoscopy and served as a control group.  
Group II: included 20 patients with IBD 
(ulcerative colitis) diagnosed endoscopically and 
pathologically. 
Group III: included 20 patients who were 
found to have colorectal polyps endoscopically and 
proved to be adenomatous pathologically and served 
as adenoma group.  
Group IV: included 40 patients with colorectal 
cancer diagnosed endoscopically and pathologically. 
Inclusion criteria: Adult patients >18 years old 
and have eligible indications for colonoscopy as 
follow:  
1. Patient with lower GIT symptoms including 
chronic diarrhoea, chronic constipation, alternating 
bowel habits and bleeding per rectum.  
2. Cases with relevant alarming symptoms 
and signs for CRC, e.g. significant unexplained weight 
loss, unexplained anaemia.  
3. Patients with remote metastases proved to 
be adenocarcinoma and were suspected to have 
CRC. 
4. Patients underwent screening for CRC. 
5. Patients who have a family or personal 
history of CRC, genetic CRC syndrome or adenomas. 
6. Patients with inflammatory bowel diseases 
were diagnosed for more than 8 years. 
7. Patients are known to have FAP, family 
history of FAP or history of previous adenomatous 
polyps. 
Exclusion criteria: Patients previously 
received chemotherapy for colorectal malignancy. 
Patients subjected to the following: Informed 
written consent, Full history taking and thorough 
clinical examination (pallor, abdominal masses). 
Laboratory investigations including Stool analysis, 
Complete blood count (CBC), erythrocyte 
sedimentation rate (ESR) and Carcino Embryonic 
Antigen (CEA). Abdominal ultrasound for scanning 
masses, metastases and lymphadenopathy. Full 
colonoscopic examination by using Pentax 
colonoscope by model number (EC 3840 L). 
 
Tissue Samples (biopsy specimens) 
Biopsies were taken from the inspected 
lesions and the nearby normal colonic mucosa. 
Biopsies were taken using a standard cold biopsy 
forceps (CFB-2.5- 230-S, Wilson Cook medical®). In 
the Control Group multiple biopsies were taken from 
the colonic mucosa in all cases while in IBD Group 
multiple biopsies were taken from the inflamed 
mucosa and multiple biopsies were taken from the 
nearby grossly normal colonic mucosa while in 
Adenomas Group polyps will be removed using a 
polypectomy snare and multiple biopsies were taken 
from the nearby mucosa and in CRC Group multiple 
biopsies were taken from cancer and multiple biopsies 
from the nearby mucosa. 
Specimens were fixed in 10% buffered 
formalin. Paraffin blocks were prepared. 
Histopathologic sections were cut at 4 μm thick. All 
slides were treated with 3-aminopropyl-triethoxysilane 
(3APTES/SIGMA-A-3648). These slides were used 
instead of the ordinary albumenised slides to minimise 
staining artefacts and for better fixation of sections on 
the slides.  
Immunohistochemical reaction was performed 
using avidin-biotin complex (ABC) immunoperoxidase 
technique. Sections were de-waxed in xylene and 
hydrated in descending grades of ethanol. 
Endogenous peroxidase activity was quenched by 
incubation in 3% hydrogen peroxide and then in 100% 
methanol for 20 minutes.  
Antigen retrieval was performed by 
microwaving the sections in citrate buffer (PH 6.0) for 
15 minutes at 700 W. Sections were incubated 
overnight at 40C with the anti-human primary 
monoclonal antibodies against Lgr5 and CD133 
(Santa Cruz Biotechnology Inc.; Santa Cruz, USA) 
 Rosiq et al. Colonic Stem Cells Expression of Lgr5 and CD133 Proteins as Predictive Markers in Colorectal Cancer 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
and diluted at 1:100 and 1:150 respectively. Next day, 
sections were washed in PBS then incubated with 
streptavidin-biotin-peroxidase complex and 
substantiated using a peroxidase/DAB 
(diaminobenzidine) enzymatic reaction for Lgr5 and 
CD133. Staining was completed by 5 to 10 minutes 
incubation with 3, 3'-diaminobenzidine 
(DAB)+substrate-chromogen which resulted in a 
brown-coloured precipitate at the antigen sites of Lrg5 
and CD133 (cytoplasmic stain). Slides were washed 
in PBS for five minutes then placed in 70%, 95% and 
100% alcohol for five minutes each. The nuclei were 
counterstained with Mayer's hematoxylin. Coverslips 
were mounted using Dpx. Positive and negative 
control slides for each marker were included in each 
session. As a negative control, liver tissue section was 
processed in the sequences mentioned above but 
with the omission of the primary antibodies. 
All immunostained slides were analysed using 
Zeis microscope with high resolution (Axio Scope, 
Germany) in ten successive high-power fields (HPFs). 
Both Lgr5 and CD133 antigens were expressed as 
brown cytoplasmic staining. Two features of immuno-
reactions were assessed separately on a semi-
quantitative basis (H score) as follows: 1) the extent of 
staining was assessed as the percentage of positively 
stained cells in 10 HPFs in the highest expression (hot 
spot) areas in each case. Then, means of 
percentages were calculated. 2) The intensity of 
staining of the positive cells was relatively designated 
as + (mild or weak), ++ (moderate), and +++ (strong) 
according to Itoi et al., [10]. Then data were converted 
to immune-histochemical score (ranged from 1 to 6) 
by multiplying intensity and extent scores. An 
immunohistochemical score of 5-6 was considered 
strong immunoreactivity and was given score 3, 3-4 
was considered moderate and was given score 2, and 
1-2 was considered weak and was given score 1. 
The data were analysed using Microsoft Excel 
2010 and Statistical Package for Social Science 
(SPSS version 22.0) for Windows (SPSS IBM., 
Chicago, IL). Results were expressed as mean ± SD 
with 95% confidence interval using mean for 
quantitative variables, frequencies and percentages 
for qualitative ones. P<0.05 was considered 
statistically significant. Quantitative data were 
analysed by applying the one-way analysis of 
variance (ANOVA) test for comparison of the mean of 
more than two groups, while independent-samples t-
test was used for comparison of the means of two 
groups. Chi-square test was used to compare 
proportions between two qualitative parameters. 
 
 
Results 
The demographic features of the whole 
studied patients and each group are summarised in 
(Table 1). 
Table 1: Age and sex of the studied groups 
Descriptive 
parameters 
Control 
group 
N = 20 
IBD 
group 
N = 20 
Adenomas 
group 
N = 20 
Malignant 
group 
N = 40 
Total patients 
N = 100 P. Value 
Age Mean±SD 55.3±15.02 30.7±7.7 40.2±12.7 53.7±15.12 44.975±18.17 0.001** 
Sex 
Female 7 (20.0%) 8 (22.9%) 12 (10.9%) 16 (45.7%) 43 (43%) 
0.9 
Male 13 (23.6%) 12 (21.8%) 8 (11.4%) 24 (43.6%) 57 (57%) 
 
Bleeding per rectum was the most common 
presentation in the studied patients; presenting 35% 
of the total patients, malignant group (37.5%), and 
adenoma group (50%). Weight loss was statistically 
highly significant (P = 0.03) in patients of the 
malignant group (80%).  
Table 2: Clinical presentation in the studied groups 
Clinical presentation 
Control 
group 
N = 20 
IBD 
group 
N = 20 
Adenomas 
group 
N = 20 
Malignant 
group 
N = 40 
Total 
patients 
N = 100 
P. Value 
Abdominal pain 8 (40.0%) 5 (25.0%) 2 (10.0%) 5 (12.5%) 20 (20.0%) 0.04* 
Bleeding per rectum 0 (0.0%) 10 (50.0%) 10 (50.0%) 15 (37.5%) 35 (35.0%) 0.001** 
Constipation 6 (30.0%) 0 (0.0%) 0 (0.0%) 3 (7.5%) 9 (9.0%) 0.003** 
Diarrhea 6 (30.0%) 0 (0.0%) 5 (25.0%) 2 (5.0%) 13 (13.0%) 0.001** 
Anemia 0 (0.0%) 2 (10.0%) 1 (5.0%) 7 (17.5%) 10 (10.0%) 0.1 
Weight loss 0 (0.0%) 0 (0.0%) 2 (10.0%) 8 (20.0%) 10 (10.0%) 0.03* 
Mucorrhea 0 (0.0%) 3 (15.0%) 0 (0.0%) 0 (10.0%) 3 (3.0%) 0.006** 
 
Mucorrhea was statistically highly significant 
(P = 0.006) in IBD group. Constipation and diarrhoea 
were statistically significant in control patients (Table 
2; Figure 1A-F). 
 
Figure 1: A) Control case of mild colitis (H & E, x 100);  B)  UC 
case, (H & E, x 100);  C) UC case with mild dysplasia, (H & E, x 
100); D) A case of CD (H & E x 100); E) A cases of well-
differentiated adenocarcinoma (GII); F) A cases of poorly 
differentiated (H & E x 400) 
 
Fungating mass was the most the most 
common endoscopic finding of CRC group (62.5%) 
while ulceration was present 60% of IBD group and 
the polypoid lesion was present 100% of adenoma 
group (Table 3). 
CEA was highly elevated in CRC group (P = 
0.001) with the high significant difference compared 
with other studied groups (370.4 mg/L vs 6.8, 6.9 and 
5.8 mg/L, respectively) (Table 4). 
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Table 3: Endoscopic findings in the studied groups 
 
Control 
group 
N = 20 
IBD 
group 
N = 20 
Adenomas 
group 
N = 20 
Malignant 
group 
N = 40 
Total 
patients 
N = 100 
P-Value 
S
it
e
 
Rectum 4 (20%) 6 (30%) 5 (25%) 10 (25 %) 25 (20%) 0.7 
Sigmoid 0 (0.0%) 0 (0.0%) 5 (25.0%) 8 (20%) 13 (13%) 0.01* 
Recto-
sigmoid 
10 (50%) 8 (40%) 4 (20%) 9 (22.5%) 31 (31%) 0.08 
Hepatic 
flexure 
6 (30%) 0 (0.0%) 3 (15.0%) 9 (22.5%) 18 (18%) 
0.07 
Caecum 0 (0.0%) 0 (0.0%) 3 (15.0%) 4 (10.0%) 7 (7%) 0.1 
Whole colon 0 (0.0%) 6 (30.0%) 0 (0.0%) 0 (0.0%) 6 (6%) 0.001** 
E
n
d
o
s
c
o
p
ic
 f
in
d
in
g
 Mass 0 (0.0%) 0 (0.0%) 0 (0.0%) 25 (62.5%) 25 (20%) 0.001** 
Angio-
dysplasia 
2 (10.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (20%) 
0.04* 
Polyp 0 (0.0%) 0 (0.0%) 20 (100.0%) 0 (0.0%) 20 (20%) 0.001** 
Hyperemia 3 (15.0%) 6 (30.0%) 0 (0.0%) 0 (0.0%) 9 (20%) 0.001** 
Ulceration 0 (0.0%) 
12 
(60.0%) 
0 (0.0%) 5 (12.5%) 17 (20%) 
0.001** 
Stricture 0 (0.0%) 2 (10.0%) 0 (0.0%) 10 (25%) 12 (20%) 0.008** 
Normal 15 (75.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 15 (20%) 0.001** 
 
Lgr5 was positive in 37 patients (92.5 %), 12 
patients (60%), 10 patients (50%), 3 patients (15%) in 
malignant, IBD, adenoma, and normal mucosa 
respectively, high statistically significance difference 
between groups at P < 0.001 (Table 5; Figure 2 A-E).  
Table 4: Laboratory investigations of the studied groups 
 
 
Control IBD Adenomas Malignant Total patients 
P. Value  N = 20 N = 20 N = 20 N = 40 N = 100 
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
L
a
b
. 
In
v
e
s
ti
g
a
ti
o
n
 
HB 13.3 ± 1.07 9.9 ± 1.01 10.9 ± .0.59 8.4 ± 16.7 11.4 ± 12.9 0.01* 
TLC 7.13 ± 2.7 8.79 ± 2.7 8.34 ± 2.4 7.94 ± 2.1 8.1 ± 12.3 0.1 
PLT 257.1 ± 111.3 215.6 ± 46.2 247.9 ± 132.9 214.15 ± 87.9 238.7 ± 92.7 0.1 
ESR 43.45 ± 21.8 61.4 ± 25.96 50.0 ± 26.9 66.7 ± 27.9 55.4 ± 24.3 0.02* 
CEA 6.8 ± 3.05 6.9 ± 2.05 5.8 ± 2.09 370.4 ± 395.6 97.5 ± 86.9 0.001** 
S
to
o
l 
F
in
d
in
g
 
Blood 6 (30.0%) 4 (20.0%) 6 (30.0%) 7 (17.5%) 23 (23%) 0.5 
Mucous 4 (20.0%) 6 (30.0%) 4 (20.0%) 7 (17.5%) 21 (21%) 0.7 
EH 5 (25.0%) 6 (30.0%) 4 (20.0%) 9 (22.5%) 24 (24%) 0.8 
Giardia 4 (20.0%) 4 (20.0%) 4 (20.0%) 11 (27.5%) 23 (23%) 0.8 
Pus 1 (5.0%) 0 (0.0%) 2 (10.0%) 6 (15.0%) 9 (9%) 0.2 
 
Four cases out of 5 (80%) of GI showed 
positive Lgr5 expression while 16 cases out of 18 
(88.8%) of GII showed positive Lgr5 and 17 cases out 
of 17 (100%) of GIII showed positive Lgr5 expression. 
There is a significant difference between GIII 
compared to GII and GI at P < 0.01 and P < 0.05 
respectively (Table 6; Figure 2 A-E). 
Table 5: Immunohistochemical staining of Lgr5 (intensity & 
extent) and CD133 of the studied groups 
 
 
Control 
N = 20 
IBD 
N = 20 
Adenomas 
N = 20 
Malignant 
N = 40 
Total 
patients 
N = 100 
P. Value 
L
g
r5
 
in
te
n
s
it
y
 
Negative 17 (85.0%) 10 (50.0%) 8 (40.0%) 3 (7.5%) 38 (38.0%) 0.001** 
Weak 3 (15.0%) 4 (20.0%) 4 (20.0%) 2 (5.0%) 13 (13.0%) 0.2 
Moderate 0 (0.0%) 6 (30.0%) 8 (40.0%) 8 (20.0%) 22 (22.0%) 0.01* 
Strong 0 (0.0%) 0 (0.0%) 0 (0.0%) 27 (67.5%) 27 (27.0%) 0.001** 
L
R
G
5
 
E
x
te
n
t 
Negative 17 (85.0%) 10 (50.0%) 8 (40.0%) 3 (7.5%) 38 (38.0%) 0.001** 
Less5 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (5.0%) 2 (2.0%) 0.3 
5-25 3 (15.0%) 2 (10.0%) 4 (20.0%) 0 (0.0%) 9 (9.0%) 0.05* 
25-50 0 (0.0%) 2 (10.0%) 0 (0.0%) 0 (0.0%) 2 (2.0%) 0.04* 
50-75 0 (0.0%) 6 (30.0%) 8 (40.0%) 8 (20.0%) 22 (22.0%) 0.01* 
75-100 0 (0.0%) 0 (0.0%) 0 (0.0%) 27 (67.5%) 27 (27.0%) 0.001** 
C
D
1
3
3
 
Negative 17 (85.0%) 6 (30.0%) 8 (40.0%) 0 (0.0%) 31 (31.0%) 0.001** 
Mild 3 (15.0%) 8 (40.0%) 6 (30.0%) 3 (7.5%) 20 (20.0%) 0.01* 
Moderate 0 (0.0%) 6 (30.0%) 6 (30.0%) 11 (27.5%) 23 (23.0%) 0.05* 
Strong 0 (0.0%) 0 (0.0%) 0 (0.0%) 26 (65.0%) 26 (26.0%) 0.001** 
 
CD133 was expressed in 40 patients (100%), 
12 patients (60%), 14 patients (70%) and 3 patients 
(15%) in malignant, adenoma, IBD and control 
patients respectively, with high statistically 
significance between different groups at P < 0.001. A 
very significant difference in CD133 expression was 
found between colorectal carcinoma and normal 
mucosa (P < 0.001) (Table 5; Figure 3 A-F). 
 
Figure 2: A) Control case of mild colitis, no expression of Lrg5 
immunostain in the cytoplasm of cells lining the colonic glands (IHC, 
DAB, x200), B) Ulcerative Colitis case, with moderate expression of 
the Lrg5 protein in the cytoplasm of cells lining the colonic gland. 
(IHC, DAB. x40), C) A case of Crohns Disease, with moderate 
expression of CD Lrg5 protein in the cytoplasm of cells lining the 
gland and crypt epithelium (red arrow)(IHC, DAB. x40), D) A cases 
of tubular adenoma, showing moderate expression of CD Lrg5 
protein in the cytoplasm of cells lining the gland(red arrow)  and 
crypt epithelium (black arrow) (IHC, DAB. x100), E) A cases of 
moderately differentiated adenocarcinoma (GII), showing marked  
expression of CD Lrg5 protein in the cytoplasm of cells lining the 
gland(red arrow)  and crypt epithelium (black arrow) (IHC, DAB. 
x100) 
 
As regards this correlation between 
immunoexpression of CD133 and histopathological 
grade, the intensity of CD133 was strong in GII 
(55.7%) and GIII (88.3%). There is a significant 
difference between GIII compared to GII and GI at 
P<0.01 and P < 0.05 respectively (Table 7; Fig. 3 A-
F). 
 
Figure 3: A)  Control case of mild colitis, showing mild expression of 
CD133 immunostain in the cytoplasm of cells lining the crypt 
epithelium( black arrow) and glands (red arrow)(IHC, DAB, x200), 
B) Ulcerative Colitis case, showing mild to moderate expression of 
CD133 immunostain in the cytoplasm of cells lining the colonic 
glands (red arrow) (IHC, DAB, x100), C) A case of Crohns Disease, 
showing moderate expression of CD133 immunostain in the 
cytoplasm of cells lining the colonic glands (red arrow) IHC,DAB, 
x100), D) A cases of tubulovillous adenoma, showing moderate 
expression of CD133 immunostain in the cytoplasm of cells lining 
the colonic glands (red arrow) ( IHC,DAB, x40), E)&F A cases of  
moderately differentiated adenocarcinoma,  showing marked 
expression of CD133 immunostain in the cytoplasm of cells lining 
the colonic glands (red arrow) (IHC, DAB, x200, x400) 
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Four cases out of 5 of Dukes' A (80%) were 
positive for Lgr5, 13 cases out of 15 of Dukes' B 
(86.6%) and 20 cases out of 20 of Dukes' C (100%) 
were positive for Lgr5. There is significant difference 
between Dukes' B and C comparing to Dukes' A at     
P < 0.01 and P < 0.05 respectively (Table 8). 
Table 6: Correlation of Lgr5 score and histopathological 
grades in the malignant group 
Histopathological  grade 
Lrg5 score  staining 
+, Mild 
Score 1)) 
No     % 
++,Moderate 
score 2)) 
No     % 
+++, Strong 
Score 3)) 
No     % 
Well differentiated (GI) 
N=5 
1 (25%) 3 (75 %) 0(0%) 
   
Moderately differentiated   ( GII) 
N=18 
1 (16,6%)** 6 (33.4%)** 9 (50%)** 
Poorly differentiated  (GIII) 
N=17 
0 (0%) 3 (5.9%)**,^ 14(94.1%)**,^ 
Cross tables, Pearson Chi-Square; P < 0.05; *p < 0.01 compared to GI group; ^p < 0.05 
compared to GII group. 
 
Three cases out of 5 of Dukes' A (60%) were 
moderately positive for CD133, 10 cases out of 15 of 
Dukes' B ( 66.7%) showed strong expression of 
CD133 and 18 cases out of 20 of Dukes' C (90%) 
were strongly positive for CD133 (Table 9). 
Table 7: Correlation of CD133 immunoexpression and 
histopathological grades in the malignant group 
Histopathological  grade 
Immunoexpression  of  CD133  staining 
+, Mild 
No     % 
++,Moderate 
No     % 
+++, Strong 
No     % 
Well differentiated,  (GI) N=5 3 (60%) 2 (40%) 0 (0%) 
Moderately differentiated, (GII)N=18 0 (0%) 2 (11.7%)**,^ 15(88.3%)**,^ 
Poorly differentiated,  (GIII) N=17 0 (0%) 2 (11.7%)**,^ 15(88.3%)**,^ 
Cross tables, Pearson Chi-Square; P < 0.05; * P < 0.05 compared to GI group; **P < 0.01 
compared to GI group; ^P < 0.05 compared to GII group. 
 
 
Discussion 
 
 Worldwide, colorectal cancer is the third 
most commonly diagnosed cancer in males and the 
second in females. Colorectal cancer (CRC) annually 
affects more than one million men and women and 
causes more than half a million deaths [1]. CRC is 
presented as a multistep genetic disorder 
characterised by specific mutations in signal 
transduction pathways. The development and 
progression from adenoma to cancer and metastatic 
disease require the simultaneous failure of protective 
mechanisms [11].  
Table 8: Correlation of Lgr5 score and histopathological stages 
in malignant group 
Histopathological  Stages 
Lrg5 score  immunoexpression 
+, Mild 
Score 1)) 
No      % 
++,Moderate  Score 
2)) 
No     % 
+++, Strong 
Score 3)) 
No     % 
Dukes' A   N=5 0( 0%) 4 (100%) 0(0%) 
Dukes' B    N=15 0 (0%) 3 (23.1%)* 10(76,9%)* 
Dukes' C    N=20 0(0%) 2 (10%)*,^ 18 (90%)*,^ 
Cross tables, Pearson Chi-Square; P < 0.05; *P < 0.01 compared to Duck A group; ^P < 
0.05 compared to Duck B group. 
 
Colorectal cancer develops from a dysplastic 
precursor lesion, regardless of whether it arises 
sporadically, in the setting of high-risk hereditary 
conditions, or in the context of chronic inflammation 
like inflammatory bowel disease (IBD). 
Table 9: Correlation of CD133 immunoexpression and 
histopathological stages malignant group 
Histopathological  Stages 
Immunoexpression  of   CD133  staining 
+, Mild 
No     % 
++,Moderate No 
    % 
+++, Strong 
No     % 
Duke A     N = 5 2 (40%) 3 (60%) 0 (0%) 
Duke B    N = 15 2 (13.3%) 3  20%)* 10 (66,7%)* 
Duke C    N = 20 0 (0%) 2 (10%)*,^ 18 (90%)*,^ 
Cross tables, Pearson Chi-Square; P < 0.05; *P < 0.01 compared to Dukes' A group; ^P < 
0.05 compared to Dukes' B group. 
 
In IBD, however, dysplasia can be polypoid or 
flat. In fact, the rather unusual macroscopic 
appearance and biologic behaviour of dysplasia in 
IBD have stimulated a good deal of research into the 
natural history and molecular pathogenesis of CRC in 
patients with IBD [12]. Cancer stem cell theory in CRC 
has been investigated, and it is based on evidence 
that only a small subset of cells, the CSCs, within the 
tumour population, can initiate and sustain tumour 
growth and several stem cell markers have been 
studied [13].  
Metastasis is responsible for approximately 
90% of cancer‐associated mortality and can be 
divided into translocation and colonisation. As the 
CSC population represents the only cells that 
propagate tumours, it can be extrapolated that these 
cells are responsible for metastasis formation. It is, 
therefore, a prerequisite that these cells must be able 
to detach from a primary tumour, invade, access, and 
survive at the circulation, disseminate at distant sites, 
transmigrate across the endothelial lining of the target 
tissue, and form secondary tumours [14] [15].  
Several markers have been identified as solid 
cancer stem cell markers. CD133 is a transmembrane 
pentaspan protein which was initially described as a 
surface antigen specific for human hematopoietic 
stem cells. Indeed, CD133 alone or in combination 
with other markers is currently used for the isolation of 
stem cells from numerous tissues, such as bone 
marrow, brain, kidney, prostate, liver, pancreas, and 
skin. Furthermore, investigators have used 
monoclonal antibodies to CD133 for the identification 
and isolation of a putative cancer stem cell population 
from malignant tumours of brain, prostate, liver, 
pancreas, lung, and colon [16].  
On the other hand protein glycoprotein 
coupled receptors (GCRs) have been investigated to 
be closely associated with tumorigenesis [17]. Lgr5 
which is one of (GCRs) members proved to be a stem 
cell marker [18]. 
This prospective study was conducted on 100 
patients presenting with colonic symptoms, attending 
to Gastrointestinal Endoscopy unit in Nasser Institute 
for research and treatment Hospital. This study was 
aiming to assess the expression of CD133 and Lgr5 in 
pre-malignant (adenomatous polyps and IBD), 
malignant colorectal lesions and normal colonic 
Basic Science 
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mucosa by immunohistochemical staining. 
According to the immunohistochemical 
results, lgr5 was detected as brown cytoplasmic 
granules with different expression pattern in the 
normal colonic mucosa, adenoma and carcinoma. Our 
results showed that Lgr5 protein was strongly 
positively (score 3) in 67.7% of cases (27/40), 
moderately (score 2) in 20% of cases (8/40) and mild 
(score 1) in 5% of cases (2/40) of colorectal 
carcinomas respectively, with high statistically 
significance difference between groups at P < 0.001. 
Statistically speaking a significant correlation was 
found between a score of lgr5 expression and the type 
of the lesion as the score increases with progression 
of the lesion from adenoma to carcinoma (P-value < 
0.01). This was in agreement with Fan et al., [18] who 
stated that 54% of colorectal carcinoma cases 
showed score group (3) of lgr5 expression. This 
means that lgr5 expression might be involved in 
colorectal carcinogenesis. 
In the current study, as regards the tumour 
grading, Lgr5 immunoexpression in CRC group. Three 
cases (80%) of GI, 16 cases (88.8%) of GII and 17 
cases (100%) of GIII with the highly statistically 
significant difference between GIII compared to GII 
and GI at P < 0.01 and P < 0.05 respectively. These 
results were in disagreement with Fan et al., [18] who 
found that no correlation was found between lgr5 
score and the grade of CRC as 34% of grade II 
showed score 1, 14.9% of grade II showed score 2 
and 4.5% showed score 3 . In grade III 86.6% of 
cases showed score (1) and 13.4% of cases showed 
score (2) and no cases showed score (3). This current 
study was in disagreement with Takeda et al., [19] 
that found lgr5 expression was not correlated to the 
degree of differentiation of CRC cases. 
These results were in contrast with Simon et 
al., [20] that found lgr5 was correlated significantly 
with tumour grade in gastric adenocarcinoma (P-value 
< 0.01). 
Concerning the expression of CD133 in CRC 
cases, the present study revealed a significant 
difference between colorectal carcinoma and normal 
mucosa (P < 0.001). CD133 was positive in 15% of 
cases (3/20) of normal mucosa (control cases). 
CD133 protein was strongly positively in intensity in 
65% of cases (26/40), moderately 27.5% of cases 
(11/40) and mild intensity of CD133 in 7.5% of cases 
(3/40) of the colorectal carcinomas respectively, with 
high statistically significance (P < 0.001). These 
findings are in agreement with Takahashi et al., [21] 
and by Yang et al., [22]. However; our results are in 
contrary to those of Hongo et al., [23], Choi et al., [24], 
Horst et al., [25] and Kojima et al., [26]. This can be 
explained by the difference in the sample size; the 
studies which disagreed with our results had a larger 
sample size. 
These findings are in agreement with those 
detected by Wang et al., [27], found that high CD133 
expression was significantly associated with 
moderately and poorly differentiated CRC. In contrast 
Coco et al., [28], stated that no significant relation 
between CD133 expression and histologic grade and 
also with that found by Hongo et al., [23], Takahashi 
et al., [21], Choi et al., [24], Horst et al., [25] and 
Saigusa et al., [29]. 
As regard Dukes' staging and Lgr5 expression 
our results showed that four cases out of 5 of Dukes' 
A (60 %) were positive for Lrgr5, 13 cases out of 15 of 
Dukes' B (86.6%) showed immunoreactivity for Lgr5, 
and 20 cases out of 20 of Dukes' C (100 %) were 
positive for Lgr5 with statistically significance 
difference (P < 0.01). There was a significant 
correlation between a score of lrg5 and the stage of 
CRC (P-value < 0.05). These results suggest that lrg5 
expression perhaps play a role not only in tumour 
initiation but also in the progression of a tumour. 
These results in agreement with Merlos et al., [30], 
Takahashi et al., [21], and Uchida et al., [31] found 
increased Lgr5 expression in advanced stages of 
CRC cases. 
Concerning the expression of CD133 in CRC 
cases in correlation to Dukes' stage, there are three 
cases out of 5 of Dukes' A (60%) were moderately 
positive for CD133, 1 cases out of 15 of Dukes' B 
(66.7%) showed strong expression of CD133, and 18 
cases out of 20 of Dukes' C (90%) were strongly 
positive for CD133. This is in contrast with results of 
Wang et al., [27], Takahashi et al., [21], Choi et al., 
[24], Horst et al., [25] and Kojima et al., [26] found no 
significant relation between CD133 expression and 
modified Dukes. Horst et al., [25] reported significant 
relation with N and M stage. The studies had different 
results from ours are much larger in the number of 
patients and also Coco et al., [28] studies have 
different cut-off used to discriminate low and high 
expression. 
In conclusion,  as stem cell marker of cells 
with intestinal differentiation, Lgr5 and CD133 were 
presented with significantly increased expression with 
progression from normal colon towards CRC. Lgr5 
expression and CD133 was positively correlated with 
stage of CRC suggesting its possible involvement in 
colorectal tumorigenesis progression and patient’s 
outcome. 
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